Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Aspect to engineer therapeutic tissues with $20M series A

Sandi Wong, Assistant Editor
January 9, 2020 11:07 PM UTC

After spending its early years validating its 3-D bioprinting technology via disease modeling in drug discovery partnerships, Aspect Biosystems raised a $20 million series A round to develop the engineered tissues as therapeutics.

New investor Radical Ventures led the University of British Columbia spinout’s financing. Existing investors Pangaea Ventures and Pallasite Ventures, new investor Rhino Ventures and undisclosed others also participated...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Aspect Biosystems Ltd.